Pacira Biosciences, Inc. (PCRX)
36.48
0.00 (0.00%)
USD |
NASDAQ |
Nov 17, 16:00
Pacira Biosciences Enterprise Value : 1.500B for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 1.500B |
| November 16, 2026 | 1.500B |
| November 13, 2026 | 1.499B |
| November 12, 2026 | 1.499B |
| November 11, 2026 | 1.499B |
| November 10, 2026 | 1.501B |
| November 09, 2026 | 1.499B |
| November 06, 2026 | 1.498B |
| November 05, 2026 | 1.498B |
| November 04, 2026 | 1.497B |
| November 03, 2026 | 1.497B |
| November 02, 2026 | 1.497B |
| October 30, 2026 | 1.497B |
| October 29, 2026 | 1.497B |
| October 28, 2026 | 1.497B |
| October 27, 2026 | 1.497B |
| October 26, 2026 | 1.496B |
| October 23, 2026 | 1.498B |
| October 22, 2026 | 1.495B |
| October 21, 2026 | 1.494B |
| October 20, 2026 | 1.496B |
| October 19, 2026 | 1.495B |
| October 16, 2026 | 1.495B |
| October 15, 2026 | 1.494B |
| October 14, 2026 | 1.497B |
| Date | Value |
|---|---|
| October 13, 2026 | 1.493B |
| October 12, 2026 | 1.495B |
| October 09, 2026 | 1.493B |
| October 08, 2026 | 1.497B |
| October 07, 2026 | 1.050B |
| October 06, 2026 | 1.033B |
| October 05, 2026 | 1.044B |
| October 02, 2026 | 1.050B |
| October 01, 2026 | 1.043B |
| September 30, 2026 | 1.044B |
| September 29, 2026 | 1.183B |
| September 28, 2026 | 1.172B |
| September 25, 2026 | 1.161B |
| September 24, 2026 | 1.179B |
| September 23, 2026 | 1.142B |
| September 22, 2026 | 1.145B |
| September 21, 2026 | 1.121B |
| September 18, 2026 | 1.144B |
| September 17, 2026 | 1.136B |
| September 16, 2026 | 1.153B |
| September 15, 2026 | 1.120B |
| September 14, 2026 | 1.144B |
| September 11, 2026 | 1.171B |
| September 10, 2026 | 1.163B |
| September 09, 2026 | 1.192B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Viatris, Inc. | 35.12B |
| Organon & Co. | 10.75B |
| ANI Pharmaceuticals, Inc. | 1.774B |
| Corcept Therapeutics, Inc. | 7.301B |
| Veru, Inc. | 13.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 28.52M |
| Revenue (Quarterly) | 176.65M |
| Total Expenses (Quarterly) | 148.13M |
| EPS Diluted (Quarterly) | 0.6985 |
| Gross Profit Margin (Quarterly) | 71.93% |
| Profit Margin (Quarterly) | 16.15% |
| Earnings Yield | 2.53% |
| Operating Earnings Yield | 2.06% |
| Normalized Earnings Yield | 2.311 |